NCT05212779View on ClinicalTrials.gov

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

Active, not recruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Epithelial Ovarian Cancer
Interventions
DIAGNOSTIC_TEST

Signatera testing

26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.

DIAGNOSTIC_TEST

Altera Testing

6ml blood and tissue sample.

Trial Locations (1)

15224

AHN West Penn Hospital, Pittsburgh

All Listed Sponsors
lead

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

OTHER